Treatment Outcomes of Real Life Elderly Multiple Myeloma Patients: A Analysis from Registry of Monoclonal Gammopathies (RMG)

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61988987%3A17110%2F18%3AA20020PH" target="_blank" >RIV/61988987:17110/18:A20020PH - isvavai.cz</a>

Result on the web

<a href="https://ashpublications.org/blood/article/132/Supplement%201/2019/261889/Treatment-Outcomes-of-Real-Life-Elderly-Multiple" target="_blank" >https://ashpublications.org/blood/article/132/Supplement%201/2019/261889/Treatment-Outcomes-of-Real-Life-Elderly-Multiple</a>

DOI - Digital Object Identifier

—

Result language

angličtina

Original language name

Treatment Outcomes of Real Life Elderly Multiple Myeloma Patients: A Analysis from Registry of Monoclonal Gammopathies (RMG)

Original language description

Introduction: Multiple myeloma patients over the age of 65 represent the majority of myeloma population. The main goal was to evaluate treatment outcomes in terms of overall survival for elderly patients based on initial choice of anti-myeloma drugs, and to find potential factors affecting survival. Patients and Methods: This is a retrospective registry based analysis from the Registry of monoclonal gammopathies of the Czech Myeloma Group. Patients with multiple myeloma diagnosed between 2007-2016 over the age of 65 with symptomatic myeloma were included in the analysis. Basic demographic data and disease characteristics were obtained. The Kaplan-Meier estimates were completed by the Greenwood confidence interval. The log-rank test was used to estimate the statistical significance of the difference between the curves. The Cox proportional hazards model was performed to explore the univariate significance of risk factors. Results: Data from 1410 MM patients were obtained. Gender [HR 1.316 (1.124-1.541), p=0.001], age [above 75 vs. 66-75, HR 1.437 (1.221-1.692), p&lt; 0.001], creatinine levels [at cutoff 152 µmol/L, HR 1.613 (1.365-1.905), p&lt; 0.001] and ECOG performance status [0-1 vs. 2-4, 1.869 (1.594-2.191), p&lt; 0.001] were found to significantly affect overall survival. Moreover these risk factors have cumulative effect on overall survival of the patients. Overall survival of patients regardless to above mentioned risk factors treated with upfront bortezomib (N = 880) was median OS 40.4 months (CI: 36.1-44.7), patients treated with upfront thalidomide (N = 370) had median OS 48.1 months (CI: 41.0-55.2), for lenalidomide (N = 64) median overall survival was 53.2 months (CI: 44.6-61.8) and for combination of bortezomib and thalidomide (N = 46) 32.2 months (CI: 26.6-37.8). When any of these risk factors was present the OS in each group shortened. In the group of patients with no risk factors (N = 255) the median OS for bortezomib (N = 126) was not reached,

Czech name

—

Czech description

—

Type

D - Article in proceedings

CEP classification

—

OECD FORD branch

30205 - Hematology

Project

—

Continuities

V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Publication year

2018

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Article name in the collection

Supplement: 1 Meeting Abstract: 2019

ISBN

—

ISSN

0006-4971

e-ISSN

1528-0020

Number of pages

1

Pages from-to

—

Publisher name

AMER SOC HEMATOLOGY, 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA

Place of publication

WASHINGTON, DC 20036 USA

Event location

San Diego

Event date

Jan 1, 2018

Type of event by nationality

WRD - Celosvětová akce

UT code for WoS article

000454837606018